Drugs / NG2 and DLL3 CAR-T cells
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT07193966 | Sep 2025 → Dec 2028 expected | melanoma | Shenzhen Geno-Immune Medical Institute | Recruiting | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | NG2 and DLL3 CAR-T cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07193966 ↗ |
| Action | Deplete | “designed to kill tumor cells through specific recognition of NG2 and DLL3” NCT07193966 ↗ |
| Modality | Cell therapy | “multiple CAR-T cell therapy” NCT07193966 ↗ |
| Route | Intravenous | “via intravenous route” NCT07193966 ↗ |
| Target | DLL3 | “targets NG2 and DLL3 surface antigens” NCT07193966 ↗ |